Cellular mechanisms underlying cognition-enhancing actions of nefiracetam (DM-9384)

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 185-188

  Yoshii, Mitsunobu ^a   Watabe, Shigeo ^b   Sakurai, Takeo ^b   Shiotani, Tadashi ^b  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

calcium channel; cholinergic system; G protein; GABAergic system; nefiracetam; passive avoidance response

Indexed keywords

4 AMINOBUTYRIC ACID; CALCIUM CHANNEL; NEFIRACETAM; NOOTROPIC AGENT; PERTUSSIS TOXIN; SCOPOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT;

EID: 0031081046     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86066-4     Document Type: Conference Paper

References (17)

1. [1] Atweh, S., Simon, J.R. and Kuhar, M.J., Utilization of sodium-dependent high affinity choline uptake in vitro as a measure of the activity of cholinergic neurons in vivo, Life Sci., 17 (1975) 1535-1544.
2. [2] Davies, L.P., Johnston, G.A.R. and Stephanson, A.L., Postnatal changes in the potassium-stimulated, calcium dependent release of radioactive GABA and glycine from slices of rat central nervous tissue, J. Neurochem., 25 (1975) 387-392.
3. [3] Fröstl, W. and Maître, L., The families of cognition enhancers, Pharmacopsychiatry, 22 (1989) 54-100.
4. [4] Gillet, G., Ammor, S. and Fillion, G., Serotonin inhibits acetylcholine release from rat striatum slices: evidence for a presynaptic receptor-mediated effect, J. Neurochem., 45 (1985) 1687-1691.
5. [5] Giurgea, D.E., The nootropic concept and its prospective implications, Drug Dev. Res., 2 (1982) 441-446.
6. [6] Graham, L.T. and Aprison, M.H., Fluorometric determination of aspartate, glutamate and γ-aminobutyrate in nerve tissue using enzymatic method, Anal. Biochem., 15 (1966) 487-497.
7. [7] Kasai, H., Voltage- and time-dependent inhibition of neuronal calcium channels by a GTP-binding protein, J. Physiol. (Lond.), 448 (1992) 189-209.
8. [8] Kojima, H., Kawajiri, S., Sakurai, T and Yamasaki, T., Effect of DM-9384, a new pyrrolidone derivative, on passive avoidance and cerebral choline acetyltransferase activity in rats. In: T. Nagasu and M. Yoshida (Eds.), Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Vol. 2, Plenum Press, New York, 1990, pp. 367-370.
9. [9] Miller, R.J., Calcium signaling in neurons, Trends Neurosci., 11 (1988) 415-419.
10. [10] Nabeshima, T., Noda, Y., Tohyama, K., Itoh, J. and Kameyama, T., Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions, Eur. J. Pharmacol., 178 (1990) 143-149.
11. A and muscarinic receptors induced by cycloheximide, J. Pharmacol. Exp. Ther., 257 (1991) 271-275.
12. [12] Narahashi, T., Tsunoo, A. and Yoshii, M., Characterization of two types of calcium channels in mouse neuroblastoma cells, J. Physiol. (Lond.), 383 (1987) 231-249.
13. [13] Okada, Y., Distribution of γ-aminobutyric acid (GABA) in the layers of superior colliculus of the rabbit, Brain Res., 75 (1974) 362-365.
14. [14] Ramsay, P.B., Krigman, M.R. and Morell, P., Developmental studies of the uptake of choline, GABA and dopamine by crude synaptosomal preparations after in vivo or in vitro lead treatment, Brain Res., 187 (1980) 383-402.
15. [15] Sakurai, T., Ojima, H., Yamasaki, T., Kojima, H. and Akashi, A., Effects of N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide (DM-9384) on learning and memory in rats, Jpn. J. Pharmacol., 50 (1989) 47-53.
16. [16] Watabe, S., Yamaguchi, H. and Ashida, S., DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex, Eur. J. Pharmacol., 238 (1993) 303-309.
17. [17] Yoshii, M. and Watabe, S., Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells, Brain Res., 642 (1994) 123-131.